ClinicalTrials.gg
TerminatedNCT00473889Updated Jul 3, 2015Results posted

A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

A Phase 2/3 interventional study of vorinostat and Comparator: paclitaxel in Stage IIIB or IV Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
The study was terminated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 19
253 · median 21
Started
2007
with 4 others
Phase 2/3
Only one
of the 20
Registered
8th of 20
by date
Lead sponsor
6 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2007, is the only one in phase 2/3, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin

03

Conditions studied

  • Stage IIIB or IV Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females at least 18 years of age who have confirmed diagnosis of Non-small Cell Lung Cancer
  • Patients with no systemic prior systemic treatment for lung cancer except patients at least 12 months from prior therapy
  • Adequate bone marrow,kidney and liver function
  • Must be recovered and at least 4 weeks from major surgery or radiation
  • (Eastern Cooperative Oncology Group) performance status of 0 or 1
  • Men and women must agree to use during the study
  • Women able to have children must have a negative pregnancy test 14 days before study enrollment

Exclusion criteria

Exclusion Criteria:

  • Patients with prior treatment with other agents less than 4 weeks before study enrollment
  • Pregnant or nursing female patients
  • Patients who are positive
  • Patients who have Hepatitis A, B, or C
  • Patients unable to take study medication by mouth
  • Patients with untreated brain cancer
  • Patient eligible for treatment with bevacizumab and for whom bevacizumab is available
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    1

    vorinostat; IV paclitaxel; IV carboplatin

    Drug: vorinostat · Drug: Comparator: paclitaxel · Drug: Comparator: carboplatin

  • Placebo comparator
    2

    Placebo; IV paclitaxel; IV carboplatin

    Drug: Comparator: paclitaxel · Drug: Comparator: carboplatin · Drug: Comparator: placebo

Interventions

  • vorinostat 400 mg capsules once daily. Up to 6 months of treatment

    Also known as: Zolinza

  • intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment

    Also known as: Taxol

  • intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.

    Also known as: Paraplatin

  • DrugComparator: placebo

    vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Defined as the time from date of randomization to death due to any cause. Patients without documented death at the time of the final analysis will be censored at the date of the last follow-up.

    Time frame: Start of treatment to death

Secondary outcomes

  1. Progression Free Survival

    Defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in sum of the longest diameter of all target lesions, the appearance of a new lesion, or an increase in non-target lesions.

    Time frame: Start of treatment to disease progression or death

  2. Number of Participants Who Had a Disease Response to Treatment

    Response to treatment is defined as a complete response (CR) or partial response (PR) to treatment. Confirmation of response required a second assessment performed at least 4 weeks after the initial assessment. (PR is defined as at least a 30% reduction in sum of the longest diameter of all target lesions and no increase in non-target lesions).

    Time frame: Every 42 days from start of treatment until disease response

07

Results

Posted Oct 12, 2009
Limitations and caveats
The study was stopped following a pre-planned interim analysis because the goal for this study to continue was not met, based on 100 events, a reduction in the hazard ratio for progression-free survival by \> 23% with a one-sided p-value \< 0.1

Participant flow

This study was conducted at 99 investigative sites worldwide. The first patient's first visit was 16 May 07 and the last patient's last visit was 12 Dec 2008.

Participant flow — Overall Study
MilestoneVorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + Carboplatin
Started126127
Completed4363
Not completed8364
Withdrew: Did not receive study medication14
Withdrew: Adverse event3017
Withdrew: Protocol violation42
Withdrew: Lack of efficacy2829
Withdrew: Lost to follow-up21
Withdrew: Physician decision105
Withdrew: Trial terminated36
Withdrew: Withdrawal by subject50

Outcome measures

PrimaryOverall Survival

Defined as the time from date of randomization to death due to any cause. Patients without documented death at the time of the final analysis will be censored at the date of the last follow-up.

Time frame:
Start of treatment to death
Reported as:
Median · Months
Overall Survival
MonthsVorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + Carboplatin
Overall Survival11.0 (0.2 to 17.3)14.0 (0.03 to 18.7)
Statistical analysis
  • Placebo + Paclitaxel + Carboplatin · Stratified Log Rank · p = 0.992 (This is a one sided p-value, which corresponds to the null hypothesis.)Disease stage and bevacizumab eligibility are the stratification factors in the stratified log rank test.
SecondaryProgression Free Survival

Defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in sum of the longest diameter of all target lesions, the appearance of a new lesion, or an increase in non-target lesions.

Time frame:
Start of treatment to disease progression or death
Reported as:
Median · Months
Progression Free Survival
MonthsVorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + Carboplatin
Progression Free Survival4.3 (0.03 to 13.4)5.5 (0.03 to 13.8)
Statistical analysis
  • Placebo + Paclitaxel + Carboplatin · Finkelstein's Interval Censored Method · p = 0.862 (This is a one sided p-value, which corresponds to the null hypothesis.)Disease stage and bevacizumab eligibility are the stratification factors in the Finkelstein's Interval Censored Method Model.
SecondaryNumber of Participants Who Had a Disease Response to Treatment

Response to treatment is defined as a complete response (CR) or partial response (PR) to treatment. Confirmation of response required a second assessment performed at least 4 weeks after the initial assessment. (PR is defined as at least a 30% reduction in sum of the longest diameter of all target lesions and no increase in non-target lesions).

Time frame:
Every 42 days from start of treatment until disease response
Reported as:
Number · Participants
Number of Participants Who Had a Disease Response to Treatment
ParticipantsVorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + Carboplatin
Responder2836
Non-Responder9787
Statistical analysis
  • Placebo + Paclitaxel + Carboplatin · Stratified Miettinen and Nurminen · p = 0.899 (This is a one sided p-value, which corresponds to the null hypothesis.)Disease stage and bevacizumab eligibility are the stratification factors in the stratified Miettinen and Nurmimen method.

Adverse events

Collected over Adverse Events were collected from the time the patient signed the informed consent form until 30 days after the last dose of study medications. Serious Adverse Events were followed until resolution.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat + Paclitaxel + Carboplatin—63/124 (50.8%)114/124 (91.9%)
Placebo + Paclitaxel + Carboplatin—45/124 (36.3%)117/124 (94.4%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventVorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + Carboplatin
PneumoniaInfections and infestations11/1249/124
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/12411/124
Febrile neutropeniaBlood and lymphatic system disorders10/1245/124
NeutropeniaBlood and lymphatic system disorders9/1242/124
AstheniaGeneral disorders6/1241/124
PyrexiaGeneral disorders5/1242/124
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1242/124
DiarrhoeaGastrointestinal disorders4/1241/124
DehydrationMetabolism and nutrition disorders4/1240/124
AnaemiaBlood and lymphatic system disorders2/1243/124
Most frequent other events
Showing 10 of 81
Most frequent other events
EventVorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + Carboplatin
Peripheral sensory neuropathyNervous system disorders51/12461/124
NeutropeniaBlood and lymphatic system disorders53/12455/124
AnaemiaBlood and lymphatic system disorders51/12442/124
AlopeciaSkin and subcutaneous tissue disorders41/12447/124
NauseaGastrointestinal disorders46/12439/124
ThrombocytopeniaBlood and lymphatic system disorders45/12423/124
DiarrhoeaGastrointestinal disorders43/12436/124
MyalgiaMusculoskeletal and connective tissue disorders21/12436/124
ConstipationGastrointestinal disorders34/12426/124
VomitingGastrointestinal disorders34/12424/124

Baseline characteristics

Age, Customized
Age, Customized(participants)Vorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + CarboplatinTotal
Less Than 65 years7089159
65 years or Older563894
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + CarboplatinTotal
Female345690
Male9271163
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + CarboplatinTotal
White7979158
Black347
Asian313263
American Indian or Alaskan Native mix131225
Cancer Stage
Cancer Stage(Participants)Vorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + CarboplatinTotal
IIIB141529
IV112112224
Eligibility to receive treatment with Bevacizumab
Eligibility to receive treatment with Bevacizumab(Participants)Vorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + CarboplatinTotal
Eligible7063133
Ineligible5560115
Unknown145
Geographic region where the participant lived
Geographic region where the participant lived(Participants)Vorinostat + Paclitaxel + CarboplatinPlacebo + Paclitaxel + CarboplatinTotal
North America252752
Europe (United Kingdom, Italy, Germany, and Spain)414081
Asia222446
Rest of the World383674
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Beaumont H, Souchet S, Labatte JM, Iannessi A, Tolcher AW. Changes of lung tumour volume on CT - prediction of the reliability of assessments. Cancer Imaging. 2015 Oct 31;15:17. doi: 10.1186/s40644-015-0052-2. PubMed 26521238 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2007
First posted
May 16, 2007
Start
May 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Oct 12, 2009
Last update
Jul 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00473889
Responsible party
Sponsor
First posted
May 16, 2007
Start date
May 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Oct 12, 2009
Last update
Jul 3, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion